Korro Bio, Inc.

Korro Bio, Inc. company information, Employees & Contact Information

Explore related pages

Korro Bio, Inc. email format Korro Bio, Inc. management contacts

Related company profiles:

Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.

Company Details

Employees
114
Address
One Kendall Square, Building 600-700,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
korrobio.com
HQ
Cambridge, Massachusetts
Competitors
Tessera Therapeutics, Verve Therapeutics, Alnylam Pharmaceuticals, Vertex Pharmaceuticals, Wave Life Sciences, Beam Therapeutics, NanoVation Therapeutics™, Entrada Therapeutics, Avenge Bio, Intellia Therapeutics, Inc..
Looking for a particular Korro Bio, Inc. employee's phone or email?

Korro Bio, Inc. Questions

News

Korro Bio, Inc. Announces Participation in September Investor and Scientific Conferences - Quiver Quantitative

Korro Bio, Inc. Announces Participation in September Investor and Scientific Conferences Quiver Quantitative

After Layoffs, Korro Bio Retains “3-2-1” Vision as It Prepares for Liftoff - Genetic Engineering and Biotechnology News

After Layoffs, Korro Bio Retains “3-2-1” Vision as It Prepares for Liftoff Genetic Engineering and Biotechnology News

Korro Bio's AATD Drug Shows Zero Safety Issues in Phase 1/2a Trial, $119.6M Cash Runway Revealed - Stock Titan

Korro Bio's AATD Drug Shows Zero Safety Issues in Phase 1/2a Trial, $119.6M Cash Runway Revealed Stock Titan

Korro Bio, Inc. Reports Q1 2025 Financial Results and Updates on KRRO-110 Development for Alpha-1 Antitrypsin Deficiency - Nasdaq

Korro Bio, Inc. Reports Q1 2025 Financial Results and Updates on KRRO-110 Development for Alpha-1 Antitrypsin Deficiency Nasdaq

Korro Appoints Loïc Vincent, Ph.D., as Chief Scientific Officer - citybiz

Korro Appoints Loïc Vincent, Ph.D., as Chief Scientific Officer citybiz

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - The Globe and Mail

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer The Globe and Mail

Disease: Alpha 1-Antitrypsin Deficiency, AATD, (NCT06677307) - CRISPR Medicine News

Disease: Alpha 1-Antitrypsin Deficiency, AATD, (NCT06677307) CRISPR Medicine News

Korro Bio: Promising Early Stage RNA Editing Company (NASDAQ:KRRO) - Seeking Alpha

Korro Bio: Promising Early Stage RNA Editing Company (NASDAQ:KRRO) Seeking Alpha

Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? - Yahoo Finance

Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? Yahoo Finance

Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency - Business Wire

Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency Business Wire

Aminobenzotriazole inhibits and induces several key drug metabolizing enzymes complicating its utility as a pan CYP inhibitor for reaction phenotyping - Wiley

Aminobenzotriazole inhibits and induces several key drug metabolizing enzymes complicating its utility as a pan CYP inhibitor for reaction phenotyping Wiley

Novo Nordisk and Korro Bio Take RNA Editing to Cardiometabolic Diseases - Inside Precision Medicine

Novo Nordisk and Korro Bio Take RNA Editing to Cardiometabolic Diseases Inside Precision Medicine

TRIA Designs Innovative 50,000-SF Headquarters for Korro Bio - Boston Real Estate Times

TRIA Designs Innovative 50,000-SF Headquarters for Korro Bio Boston Real Estate Times

KRRO Stock Price and Chart — NASDAQ:KRRO - TradingView

KRRO Stock Price and Chart — NASDAQ:KRRO TradingView

Korro Bio and Frequency Therapeutics to merge - Labiotech.eu

Korro Bio and Frequency Therapeutics to merge Labiotech.eu

Korro Bio and Frequency Therapeutics Merge - citybiz

Korro Bio and Frequency Therapeutics Merge citybiz

Korro Bio price target lowered to $53 from $130 at H.C. Wainwright - Yahoo Finance

Korro Bio price target lowered to $53 from $130 at H.C. Wainwright Yahoo Finance

Korro Bio Appoints Shelby Walker, JD, as Senior Vice President - citybiz

Korro Bio Appoints Shelby Walker, JD, as Senior Vice President citybiz

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates Yahoo Finance

Korro Bio Appoints Dr. Steve Colletti as Chief Scientific Officer - citybiz

Korro Bio Appoints Dr. Steve Colletti as Chief Scientific Officer citybiz

Korro Bio to Begin RNA-Editing Trial in Alpha-1 Antitrypsin Deficiency - CRISPR Medicine News

Korro Bio to Begin RNA-Editing Trial in Alpha-1 Antitrypsin Deficiency CRISPR Medicine News

Korro Bio’s SWOT analysis: RNA editing pioneer’s stock faces pivotal phase - Investing.com

Korro Bio’s SWOT analysis: RNA editing pioneer’s stock faces pivotal phase Investing.com

Korro Bio - The Pharma Letter

Korro Bio The Pharma Letter

Korro Bio merges with off-pitch Frequency, hits Wall Street with $117M - Fierce Biotech

Korro Bio merges with off-pitch Frequency, hits Wall Street with $117M Fierce Biotech

Korro Bio CFO Vineet Agarwal Resigns, Interim Appointed - TipRanks

Korro Bio CFO Vineet Agarwal Resigns, Interim Appointed TipRanks

Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. - Investor's Business Daily

Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. Investor's Business Daily

100-employee biotech opens new Kendall Square HQ - The Business Journals

100-employee biotech opens new Kendall Square HQ The Business Journals

Frequency Change: Korro Bio Edits Its Message, Rewrites Its Future with Reverse Merger - Genetic Engineering and Biotechnology News

Frequency Change: Korro Bio Edits Its Message, Rewrites Its Future with Reverse Merger Genetic Engineering and Biotechnology News

Korro Bio - Vineet Agarwal Announces Intention To Resign From His Position Of CFO - TradingView

Korro Bio - Vineet Agarwal Announces Intention To Resign From His Position Of CFO TradingView

We're Not Very Worried About Korro Bio's (NASDAQ:KRRO) Cash Burn Rate - Yahoo Finance

We're Not Very Worried About Korro Bio's (NASDAQ:KRRO) Cash Burn Rate Yahoo Finance

Korro Bio, Inc. (KRRO) - Zacks Investment Research

Korro Bio, Inc. (KRRO) Zacks Investment Research

Companies like Korro Bio, Inc.

Tessera Therapeutics logo - Similar company to Korro Bio, Inc.

Tessera Therapeutics

326
Avenge Bio logo - Similar company to Korro Bio, Inc.

Avenge Bio

2
Alnylam Pharmaceuticals logo - Similar company to Korro Bio, Inc.

Alnylam Pharmaceuticals

2.58K
Intellia Therapeutics, Inc. logo - Similar company to Korro Bio, Inc.

Intellia Therapeutic...

446
Verve Therapeutics logo - Similar company to Korro Bio, Inc.

Verve Therapeutics

309
Entrada Therapeutics logo - Similar company to Korro Bio, Inc.

Entrada Therapeutics

191
Wave Life Sciences logo - Similar company to Korro Bio, Inc.

Wave Life Sciences

361
Beam Therapeutics logo - Similar company to Korro Bio, Inc.

Beam Therapeutics

557
NanoVation Therapeutics™ logo - Similar company to Korro Bio, Inc.

Nanovation Therapeut...

47
Vertex Pharmaceuticals logo - Similar company to Korro Bio, Inc.

Vertex Pharmaceuticals

6.09K

Top Korro Bio, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant